Continuous Glucose Monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

Dexcom's CGM systems include sensors for placement on the back of the arm or lower abdomen. They also include the option of ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products ...

Dexcom (DXCM) stock is down over 40% in Friday's session after the continuous glucose monitoring technology company fell short of revenue estimates for its second quarter and slashed its full-year ...

Furthermore, you'd generally like to see... Investing.com -- Baird upgraded DexCom Inc (NASDAQ:DXCM). to "Outperform" from "Neutral," citing progress in U.S. sales and upcoming catalysts.

Entering 2025, these battered stocks look pretty undesirable for investors right now. But all hope isn't, and shouldn't be, lost on these companies. Here's why these stocks could make comebacks this ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their continuous glucose monitors for people with diabetes—just weeks after a ...

Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month ...

DexCom is a leader in the continuous glucose monitoring (CGM) market, or devices that help diabetes patients track their blood glucose levels. The company encountered some issues in 2024, including ...